Rapid attenuation of anti–SARS–CoV‐2 antibodies in patients with musculoskeletal diseases in whom intensive immunosuppressive therapies were reinitiated after COVID‐19: comment on the article by Curtis et al

the cohort, BVAS data were provided for 28 (43%), but this was not included in the analysis as the proportion of missing data was deemed too high. Of the patients who died, 11 of 18 were deemed to be in remission by the treating clinician at the time of COVID-19 diagnosis, 5 of 18 had moderate disease activity, and 2 of 18 had minimal disease activity. The cause of death in all patients was deemed likely, or highly likely, to be attributable to COVID-19. Clinical information was incomplete for 1 patient; this patient’s death was presumed to be attributable to COVID-19, and there was no mention of active vasculitis at any point in the case report form. In 1 other patient, active vasculitis was considered to be the possible cause of death, but on balance, COVID-19 was deemed the more likely cause.